Table 2. Patient Characteristics of patients that developed D835 Mutation upon clinical resistance to FLT3 inhibitors.

Patient	Age	# Prior Treatments	Baseline					Best response to FLT3 inhibitor	At Disease Progression					Treatment after FLT3 Inhibitor	Response
			WBC (x109/L)	PBB (%)	BMB (%)	Ratio Allele Burden ITD	Cytogenetic		WBC (x109/L)	PBB (%)	BMB (%)	Ratio Allele Burden ITD/D835	Cytogenetic
1	37	2	2.4	33	66	ND	Misc	CRp	20.5	81	56	ND	ND	IA+ Sorafenib	NR
2	87	1	7.1	89	80	ND	Dip	BMBR	23	81	82	ND	Dip	Azacytadine + Sorafenib	NR
3	69	2	5.4	20	86	Size 371 and 39.7%	Dip	CR	14	71	91	0.47/0.5 3	Dip	Phase 1 Protocol	NR
4	25	4	1.7	33	60	ND	Com	NR	10.1	97	76	ND	Com	Phase 1 Protocol	NR
5	79	1	21	51	52	0.007 and 0.167	Dip	NR	5.1	25	63	0.029 and 0.318/0. 210	Dip	Azacytadine + Sorafenib	NR
6	38	5	9.8	85	95	ND	Dip	NR	17.9	63	70	ND	Dip	Sorafenib	NR
7	43	1	60	95	92	0.384	-7	CRp	28	86	47	0.388/0. 265	Dip	Plerixafor + Sorafenib	NR
8	23	4	74	92	86	ND	ND	NR	67	96	88	ND	Com	Phase 1 Protocol	NR
9*	21	2	3	13	55	ND	−7q	NR	1.8	0	23	0.231/0. 384	−7q	SCT	Relapsed within 2 months
10	67	2	60	58	66	0.26	Dip	BMBR	13.9	83	55	0.023/0. 33	Dip	Plerixafor + Sorafenib. FA	NR
11	38	4	7.8	90	90	ND	Com	NR	43	91	80	ND	Com	Decitabine + GO	NR
12*	33	3	0.2	0	25	0.065	Ins	BMBR	23	67	74	0.124/0. 134	Misc	SCT	Relapsed within 3 months
13	52	2	19.2	89	93	ND	Misc	CRp	105	55	80	ND	Misc	Phase 1 Protocol	NR
14	75	2	65.2	1	40	ND	Dip	CR	37.6	6	32	0.856/0.393	Dip	Plerixafor + Sorafenib	NR
15	64	2	1.6	6	20	ND	Dip	NR	2.6	80	78	Ratio 0.01/0.159	ND	ND	NR

WBC: White Blood Cells, PBB: Peripheral Blood Blasts, BMB: Bone Marrow Blasts, CR: Complete Remission, CRp: Complete Remission with incomplete platelet recovery, NR: No Response, BMBR: Bone Marrow Blast Reduction, ND: Not Done, Dip: Diploid, Misc: Miscellaneous, Insu: Insufficient, Com: Complex, I: Idarubicin, F: Fludarabine, A: Ara C, GO: gemtuzumab Ozogamicin, SCT: Stem Cell Transplant.

^*These 2 patients had documented combined ITD/D835 mutation at the time of disease progression after transplantation.